Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond

References

• Wilson MP, Pepper D, Currier GW, et al. The psychopharmacology of agitation: consensus statement of the American association for emergency psychiatry project beta psychopharmacology workgroup. West J Emerg Med. 2012;13(1):26–34.
   PubMedGoogle Scholar
• Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. World J Biol Psychiatry. 2016;17(2):86–128.
   PubMed Web of Science ®Google Scholar
• Patel MX, Sethi FN, Barnes TR, et al. Joint bap napicu evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. J Psychopharmacol. 2018;32(6):601–640.
   PubMed Web of Science ®Google Scholar
• Zeller SL, Citrome L. Managing agitation associated with schizophrenia and bipolar disorder in the emergency setting. West J Emerg Med. 2016;17(2):165–172.
   PubMedGoogle Scholar
• Roberts J, Gracia Canales A, Blanthorn-Hazell S, et al. Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia. BMC Psychiatry. 2018;18(1):104.
   PubMedGoogle Scholar
• San L, Marksteiner J, Zwanzger P, et al. State of acute agitation at psychiatric emergencies in Europe: the stage study. Clin Pract Epidemiol Ment Health. 2016;12(1):75–86.
   PubMedGoogle Scholar
• Boudreaux ED, Allen MH, Claassen C, et al. The psychiatric emergency research collaboration-01: methods and results. Gen Hosp Psychiatry. 2009;31(6):515–522.
   PubMed Web of Science ®Google Scholar
• Mi W, Zhang S, Liu Q, et al. Prevalence and risk factors of agitation in newly hospitalized schizophrenia patients in China: an observational survey. Psychiatry Res. 2017;253:401–406.
   PubMed Web of Science ®Google Scholar
• Zareifopoulos N, Panayiotakopoulos G. Treatment Options for Acute Agitation in Psychiatric Patients: theoretical and Empirical Evidence. Cureus. 2019;11(11):e6152.
   PubMed Web of Science ®Google Scholar
• Guerrero-Figueroa R, Gallant DM, Downer R. Effects of dibenzoxazepine on cortical and subcortical structures of the central nervous system in the cat: prediction of the potential antipyschotic effects in man. Curr Ther Res Clin Exp. 1968;10(2):88–100.
   PubMed Web of Science ®Google Scholar
• Schaefer GJ, Michael RP. Drug interactions on spontaneous locomotor activity in rats. Neuroleptics and amphetamine-induced hyperactivity. Neuropharmacology. 1984;23(8):909–914.
   PubMed Web of Science ®Google Scholar
• Schmidek WR, Timo-Iaria C, Schmidek M, et al. Influence of loxapine on the sleep-wakefulness cycle of the rat. Pharmacol Biochem Behav. 1974;2(6):747–751.
   PubMed Web of Science ®Google Scholar
• Latimer CN. Neuropharmacologic evaluation of oxilapine, a potent psychoactive agent. J Pharmacol Exp Ther. 1969;166(1):151–162.
   PubMed Web of Science ®Google Scholar
• Stille G. Arousal inhibiting and catalepsy in neuroleptic drugs. Arzneimittelforschung. 1966;16(2):255–256.
   PubMedGoogle Scholar
• Charalampous KD, Freemesser GF, Malev J, et al. Loxapine succinate: a controlled double-blind study in schizophrenia. Curr Ther Res Clin Exp. 1974;16(8):829–837.
   PubMed Web of Science ®Google Scholar
• Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp. 1976;19(1):99–104.
   PubMed Web of Science ®Google Scholar
• van der Velde CD, Kiltie H. Effectiveness of loxapine succinate in acute schizophrenia: a comparative study with thiothixene. Curr Ther Res Clin Exp. 1975;17(1):1–12.
   PubMed Web of Science ®Google Scholar
• Cousin FR, Chabannes JP, Guedj MJ, et al. Approche thérapeutique d’une population de patients présentant des troubles psychotiques aigus ou chroniques: enquête RÉALITÉ (Recherche Épidémiologique sur l’Activité de la Loxapine et ses Indications en Thérapeutique quotidiennE). L’Encéphale. 2006;32(4):466–473.
   PubMedGoogle Scholar
• Cousin F-R, Samuelian J-C, Saoud M, et al. RÉALITÉ LT: recherche Épidémiologique sur l’Activité de la Loxapine et ses Indications en Thérapeutique quotidiennE lors d’une utilisation à Long Terme. Étude pharmacoépidémiologique: sémiologie et stratégie thérapeutique d’une population de patients présentant des troubles schizophréniques traités par loxapine. L’Encéphale. 2012;38(1):64–74.
   PubMed Web of Science ®Google Scholar
• Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473(7346):221–225.
   PubMed Web of Science ®Google Scholar
• Labuzek K, Kowalski J, Gabryel B, et al. Chlorpromazine and loxapine reduce interleukin-1β and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005;15(1):23–30.
   PubMed Web of Science ®Google Scholar
• Yang C-Y, Hsu C-Y, Fang C-S, et al. Loxapine, an antipsychotic drug, suppresses intracellular multiple-antibiotic-resistant salmonella enterica serovar typhimurium in macrophages. J Microbiol Immunol Infect. 2019;52(4):638–647.
   PubMedGoogle Scholar
• Odhar HA, Ahjel SW, Albeer AAMA, et al. Molecular docking and dynamics simulation of fda approved drugs with the main protease from 2019 novel coronavirus. Bioinformation. 2020;16(3):236–244.
   PubMed Web of Science ®Google Scholar
• Lu R, Bausch AE, Kallenborn-Gerhardt W, et al. Slack channels expressed in sensory neurons control neuropathic pain in mice. J Neurosci. 2015;35(3):1125–1135.
   PubMed Web of Science ®Google Scholar
• Biton B, Sethuramanujam S, Picchione KE, et al. The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2). J Pharmacol Exp Ther. 2012;340(3):706–715.
   PubMed Web of Science ®Google Scholar
• Ostinelli EG, Brooke-Powney MJ, Li X, et al. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev. 2017;7: CD009377. 10.1002/14651858.CD009377.pub3.
   PubMedGoogle Scholar
• Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441–448.
   PubMed Web of Science ®Google Scholar
• Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl). 2006;188(3):281–292.
   PubMed Web of Science ®Google Scholar
• Lim HK, Kim JJ, Pae CU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81–86.
   PubMed Web of Science ®Google Scholar
• Villari V, Rocca P, Fonzo V, et al. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):405–413.
   PubMed Web of Science ®Google Scholar
• Harbin. Loxapine. Public domain. Wikimedia commons. 2009 [cited 2020 Jun 8]; Available from: https://commons.wikimedia.org/wiki/File:Loxapine.svg
   Google Scholar
• Heel RC, Brogden RN, Speight TM, et al. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978;15(3):198–217.
   PubMed Web of Science ®Google Scholar
• Cottereau MJ, Poirier MF, Loo H, et al. Loxapine succinate: a new neuroleptic. L’Encephale. 1979;5(3):251–267.
   PubMedGoogle Scholar
• DePaulo JR Jr., Ayd FJ Jr. Loxapine: fifteen years’ clinical expenence. Psychosomatics. 1982;23(3):261–271.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Bagnall A, and Chue P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev. 2007;(4):CD001943. DOI:10.1002/14651858.CD001943.pub2.
   PubMed Web of Science ®Google Scholar
• Popovic D, Nuss P, Vieta E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14(1):15.
   PubMedGoogle Scholar
• Harbin. Clozapine. Pubchem. Public domain. 2009 [cited 2020 Jun 8]; Available from: https://en.wikipedia.org/wiki/Clozapine#/media/File:Clozapine.svg
   Google Scholar
• Vaccinationist. Chlorpromazine on pubchem. Public domain. 2015 [cited 2020 Jun 8]; Available from: https://en.wikipedia.org/wiki/Chlorpromazine#/media/File:Chlorpromazine.svg
   Google Scholar
• Fvasconcellos. Haloperidol. Pubchem. Public domain. 2007 [cited 2020 Jun 8]; Available from: https://en.wikipedia.org/wiki/Haloperidol#/media/File:Haloperidol.svg
   Google Scholar
• FDA. Food and drug administration. Loxapine. Drugs@fda. 2012 [cited 2020 Jul 10]; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process
   Google Scholar
• EMA. European medicines agency. Human medicines. European public assessment reports. Adasuve. 2019 [cited 2020 Jul 10]; Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve
   Google Scholar
• Valdes J, Shipley T, Rey JA. Loxapine inhalation powder (Adasuve): a new and innovative formulation of an antipsychotic treatment for agitation. P&t. 2014;39:621–623, 648.
   PubMedGoogle Scholar
• VIDAL. Loxapac. 2020 [cited 2020 Nov 4]; Available from: https://eurekasante.vidal.fr/medicaments/vidal-famille/medicament-mloxap01-LOXAPAC.html
   Google Scholar
• Singh AN, Barlas C, Singh S, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996;21(1):29–35.
   PubMed Web of Science ®Google Scholar
• Phillips ST, de Paulis T, Baron BM, et al. Binding of 5H-Dibenzo[b,e][1,4]diazepine and Chiral 5H-Dibenzo[a,d]cycloheptene Analogs of clozapine to dopamine and serotonin receptors. J Med Chem. 1994;37(17):2686–2696.
   PubMed Web of Science ®Google Scholar
• Liegeois J-F, Deville M, Dilly S, et al. New pyridobenzoxazepine derivatives derived from 5-(4-Methylpiperazin-1-yl)-8-chloro-pyrido[2,3- b][1,5]benzoxazepine (JL13): chemical synthesis and pharmacological evaluation. J Med Chem. 2012;55(4):1572–1582.
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526.
   PubMed Web of Science ®Google Scholar
• Richelson E, Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol. 1984;103(3–4):197–204.
   PubMed Web of Science ®Google Scholar
• Ferreri F, Drapier D, Baloche E, et al. The in vitro actions of loxapine on dopaminergic and serotonergic receptors. Time to consider atypical classification of this antipsychotic drug? Int J Neuropsychopharmacol. 2018;21(4):355–360.
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Remington G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT 2 and D 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry. 1997;154(11):1525–1529.
   PubMed Web of Science ®Google Scholar
• Stille G. [Neuroleptic therapy of schizophrenia from pharmacological viewpoint]. Schweiz Med Wochenschr. 1969;99(46):1645–1652.
   PubMedGoogle Scholar
• Stille G. [Therapy of schizophrenia with neuroleptics from the pharmacologic viewpoint]. Schweiz Med Wochenschr. 1969;99(47):1690–1693.
   PubMedGoogle Scholar
• Mulas A, Crabai F, Pepeu G. The influence of repeated experience on the effects of scopolamine and of amphetamine on exploratory behaviour in the rat. Pharmacol Res Commun. 1970;2(3):169–176.
   Google Scholar
• Asper H, Baggiolini M, Burki HR, et al. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur J Pharmacol. 1973;22(3):287–294.
   PubMed Web of Science ®Google Scholar
• Stille G, Hippius H. Kritische Stellungnahme zum Begriff der Neuroleptika. Pharmacopsychiatry. 1971;4(4):182–191.
   Google Scholar
• Simpson GM, Cooper TB, Lee JH, et al. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology (Berl). 1978;56(2):225–232.
   PubMed Web of Science ®Google Scholar
• Cooper SF, Dugal R, Bertrand MJ. Determination of loxapine in human plasma and urine and identification of three urinary metabolites. Xenobiotica. 1979;9(7):405–414.
   PubMed Web of Science ®Google Scholar
• Cooper TB, Kelly RG. Glc analysis of loxapine, amoxapine, and their metabolites in serum and urine. J Pharm Sci. 1979;68(2):216–219.
   PubMed Web of Science ®Google Scholar
• Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol. 1993;31(4):177–183.
   PubMedGoogle Scholar
• Luo JP, Vashishtha SC, Hawes EM, et al. In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011;32(7):398–407.
   PubMed Web of Science ®Google Scholar
• Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169–179.
   PubMed Web of Science ®Google Scholar
• Spyker DA, Riesenberg RA, Cassella JV. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol. 2015;55(9):985–994.
   PubMed Web of Science ®Google Scholar
• Takahashi LH, Huie K, Spyker DA, et al. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit. 2014;36(5):618–623.
   PubMed Web of Science ®Google Scholar
• Selim S, Riesenberg R, Cassella J, et al. Pharmacokinetics and safety of single-dose inhaled loxapine in children and adolescents. J Clin Pharmacol. 2017;57(10):1244–1257.
   PubMed Web of Science ®Google Scholar
• Huie K, Reed A, and Takahashi L, et al. Characterization of loxapine human metabolism. 15th north american regional international society for the study of xenobiotics meeting (abstract no. 288); San Diego, California, USA; 2008. [cited 2020 Jul 28]; Available from: https://www.researchgate.net/publication/268138916_Characterization_of_Loxapine_Human_Metabolism
   Google Scholar
• Coupet J, Rauh CE. 3h-spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. Eur J Pharmacol. 1979;55(2):215–218.
   PubMed Web of Science ®Google Scholar
• Wong YC, Wo SK, Zuo Z. Investigation of the disposition of loxapine, amoxapine and their hydroxylated metabolites in different brain regions, CSF and plasma of rat by LC–MS/MS. J Pharm Biomed Anal. 2012;58:83–93.
   PubMed Web of Science ®Google Scholar
• Wong YC, Zuo Z. Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in pk/pd of intranasal cns drugs. Pharm Res. 2013;30(9):2368–2384.
   PubMed Web of Science ®Google Scholar
• Coupet J, Szucs VA, Greenblatt EN. The effects of 2-chloro-11-(4-methyl-l-piperazinyl)-dibenz[b,f] [1,4]oxazepine (loxapine) and its derivatives on the dopamine-sensitive adenylate cyclase of rat striatal homogenates. Brain Res. 1976;116(1):177–180.
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Neuropsychiatr Dis Treat. 2019;15:2273–2283.
   PubMed Web of Science ®Google Scholar
• de Berardis D, Fornaro M, and Orsolini L, et al. The role of inhaled loxapine in the treatment of acute agitation in patients with psychiatric disorders: a clinical review. Int J Mol Sci. 2017;18(2):349. DOI: 10.3390/ijms18020349
   Web of Science ®Google Scholar
• Currier G, Walsh P. Safety and efficacy review of inhaled loxapine for treatment of agitation. Clinical Schizophrenia & Related Psychoses. 2013;7(1):25–32.
   PubMedGoogle Scholar
• Clark ML, Paredes A, Costiloe JP, et al. Loxapine in newly admitted chronic schizophrenic patients. J Clin Pharmacol. 1975;15(4):286–294.
   PubMed Web of Science ®Google Scholar
• Clark ML, Huber WK, Sullivan J, et al. Evaluation of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System. 1972;33(12):783–791.
   PubMedGoogle Scholar
• Selman FB, McClure RF, Helwig H. Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics. Curr Ther Res Clin Exp. 1976;19(6):645–652.
   PubMed Web of Science ®Google Scholar
• Clark ML, Paredes A, and Costiloe JP, et al. Evaluation of two dose levels of loxapine succinate in chronic schizophrenia. Diseases of the Nervous System. 1977;38(1):7–10.
   PubMedGoogle Scholar
• O’Connell RA, Jeewa M, Allen K. Loxapine concentrate in acute schizophrenia. Curr Ther Res Clin Exp. 1977;21(1):101–107.
   PubMed Web of Science ®Google Scholar
• Wittkopp TA. Evaluation of loxapine hydrochloride oral concentrate (loxitane C) in acute schizophrenia. J Clin Psychiatry. 1978;39(2):154–157.
   PubMed Web of Science ®Google Scholar
• Thomas JL. Loxapine oral liquid concentrate in the treatment of young adult patients with acute schizophrenic symptoms. Curr Ther Res Clin Exp. 1979;25:371–377.
   Web of Science ®Google Scholar
• Selkin J. Loxitane®-c (loxapine succinate) oral liquid concentrate in the rapid tranquilization of acutely disturbed schizophrenic patients. Curr Ther Res. 1979;26:908–919.
   Web of Science ®Google Scholar
• Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry. 1986;47(3):126–129.
   PubMed Web of Science ®Google Scholar
• Fruensgaard K, Korsgaard S, Jorgensen H, et al. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand. 1977;56(4):256–264.
   PubMed Web of Science ®Google Scholar
• Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp. 1977;21(1):80–100.
   PubMed Web of Science ®Google Scholar
• Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry. 1986;47(6):294–297.
   PubMed Web of Science ®Google Scholar
• Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011;198(1):51–58.
   PubMed Web of Science ®Google Scholar
• Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar i disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012;14(1):31–40.
   PubMed Web of Science ®Google Scholar
• Allen MH, Feifel D, Lesem MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(10):1313–1321.
   PubMed Web of Science ®Google Scholar
• Brauzer B, Goldstein BJ, Steinbook RM, et al. The treatment of mixed anxiety and depression with loxapine: a controlled comparative study. J Clin Pharmacol. 1974;14(8–9):455–463.
   PubMed Web of Science ®Google Scholar
• Rickels K, Weise CC, Feldman H, et al. Loxapine in neurotic anxiety: some modifiers of treatment response. J Int Med Res. 1978;6(3):180–185.
   PubMed Web of Science ®Google Scholar
• Borsboom D. A network theory of mental disorders. World Psychiatry. 2017;16(1):5–13.
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063–2071.
   PubMed Web of Science ®Google Scholar
• Burley K, Upthegrove R, Birchwood M, et al. ‘Schizophrenia postdrome’: a study of low-level psychotic experience after remission of first-episode schizophrenia. Early Interv Psychiatry. 2009;3(4):296–299.
   PubMed Web of Science ®Google Scholar
• Temmingh H, Stein DJ. Anxiety in patients with schizophrenia: epidemiology and management. CNS Drugs. 2015;29(10):819–832.
   PubMed Web of Science ®Google Scholar
• Resnick SG, Bond GR, Mueser KT. Trauma and posttraumatic stress disorder in people with schizophrenia. J Abnorm Psychol. 2003;112(3):415–423.
   PubMed Web of Science ®Google Scholar
• Peleikis DE, Varga M, Sundet K, et al. Schizophrenia patients with and without post-traumatic stress disorder (ptsd) have different mood symptom levels but same cognitive functioning. Acta Psychiatr Scand. 2013;127(6):455–463.
   PubMed Web of Science ®Google Scholar
• Eisner E, Drake R, Lobban F, et al. Comparing early signs and basic symptoms as methods for predicting psychotic relapse in clinical practice. Schizophr Res. 2018;192:124–130.
   PubMed Web of Science ®Google Scholar
• Hall J. Schizophrenia — an anxiety disorder? Br J Psychiatry. 2017;211(5):262–263.
   PubMed Web of Science ®Google Scholar
• Dubin WR, Waxman HM, Weiss KJ, et al. Rapid tranquilization: the efficacy of oral concentrate. J Clin Psychiatry. 1985;46(11):475–478.
   PubMed Web of Science ®Google Scholar
• McDowell M, Nitti K, Kulstad E, et al. Clinical outcomes in patients taking inhaled loxapine, haloperidol, or ziprasidone in the emergency department. Clin Neuropharmacol. 2019;42(2):23–26.
   PubMed Web of Science ®Google Scholar
• San L, Estrada G, Oudovenko N, et al. Placid study: a randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder. Eur Neuropsychopharmacol. 2018;28(6):710–718.
   PubMed Web of Science ®Google Scholar
• Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329(3):162–167.
   PubMed Web of Science ®Google Scholar
• Vanelle JM, Olie JP, Levy-Soussan P. New antipsychotics in schizophrenia: the French experience. Acta Psychiatr Scand Suppl. 1994;89(s380):59–63.
   Google Scholar
• Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatry. 1998;172(2):106–109.
   PubMedGoogle Scholar
• Zohar J, Stahl S, Moller H-J, et al. A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. Eur Neuropsychopharmacol. 2015;25(12):2318–2325.
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951.
   PubMed Web of Science ®Google Scholar
• Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry. 2014;75(Suppl 1):21–26.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Samalin L, et al. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase iii clinical trials of schizophrenia-targeted therapies as found in us and eu clinical trial registries. Expert Opin Pharmacother. 2016;17(7):921–936.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry. 1999;60 Suppl 10(Suppl 10):31–41.
   PubMedGoogle Scholar
• Dural A, Atay MB, Akbostanci C, et al. Impairment, disability, and life satisfaction in Parkinson’s disease. Disabil Rehabil. 2003;25(7):318–323.
   PubMed Web of Science ®Google Scholar
• Zach H, Dirkx MF, Roth D, et al. Dopamine-responsive and dopamine-resistant resting tremor in Parkinson disease. Neurology. 2020;95(11):e1461–e1470.
   PubMed Web of Science ®Google Scholar
• Yaw TK, Fox SH, Lang AE. Clozapine in parkinsonian rest tremor: a review of outcomes, adverse reactions, and possible mechanisms of action. Mov Disord Clin Pract. 2016;3(2):116–124.
   PubMedGoogle Scholar
• APDA. American Parkinson’s disease association. Medications to be avoided or used with caution in Parkinson’s disease. 2018 [cited 2022 Jun 16]; Available from: https://www.apdaparkinson.org/wp-content/uploads/2018/05/APDA-Meds_to_Avoid.pdf
   Google Scholar
• Spyker DA, Voloshko P, Heyman ER, et al. Loxapine delivered as a thermally generated aerosol does not prolong qtc in a thorough qt/qtc study in healthy subjects. J Clin Pharmacol. 2014;54(6):665–674.
   PubMed Web of Science ®Google Scholar
• Garay RP, Citrome L, Grossberg GT, et al. Investigational drugs for treating agitation in persons with dementia. Expert Opin Investig Drugs. 2016;25(8):973–983.
   PubMed Web of Science ®Google Scholar
• Elliott A, Mork TJ, Hojlund M, et al. Qtc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy. CNS Spectr. 2018;23(4):278–283.
   PubMed Web of Science ®Google Scholar
• Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimers Dis Rep. 2018;2(1):1–26.
   PubMedGoogle Scholar
• Carlyle W, Ancill RJ, Sheldon L. Aggression in the demented patient: a double-blind study of loxapine versus haloperidol. Int Clin Psychopharmacol. 1993;8(2):103–108.
   PubMed Web of Science ®Google Scholar
• Yu X, Ye Z, Houston CM, et al. Wakefulness is governed by gaba and histamine cotransmission. Neuron. 2015;87(1):164–178.
   PubMed Web of Science ®Google Scholar
• Nicholson AN, Pascoe PA, Turner C, et al. Sedation and histamine h1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol. 1991;104(1):270–276.
   PubMed Web of Science ®Google Scholar
• Squires RF, Saederup E. Mono n-aryl ethylenediamine and piperazine derivatives are gabaa receptor blockers: implications for psychiatry. Neurochem Res. 1993;18(7):787–793.
   PubMed Web of Science ®Google Scholar
• Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–270.
   PubMed Web of Science ®Google Scholar
• Schmiedl S, Peters D, Schmalz O, et al. Loxapine for treatment of patients with refractory, chemotherapy-induced neuropathic pain: a prematurely terminated pilot study showing efficacy but limited tolerability. Front Pharmacol. 2019;10:838.
   PubMed Web of Science ®Google Scholar
• Rastogi A, Ameen KM, Al-Baghdadi M, et al. Autosomal dominant polycystic kidney disease: updated perspectives. Ther Clin Risk Manag. 2019;15:1041–1052.
   PubMed Web of Science ®Google Scholar
• Paul P, Ramachandran S, Xia S, et al. Dopamine receptor antagonists as potential therapeutic agents for adpkd. PLoS One. 2019;14(5):e0216220.
   PubMed Web of Science ®Google Scholar